Scarica l'app Stockscreener
15.78
6.41%
0.95
Agomab Therapeutics Nv Adr Borsa (AGMB) Ultime notizie
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
symbol__ Stock Quote Price and Forecast - cnn.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
Agomab Proposes New Board Members and Plans Warrant Adjustment Ahead of September 11 Meetings - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE) - The Globe and Mail
Agomab Posts Half-Year 2026 Results, Advances Fibro-Inflammation Pipeline After Nasdaq IPO - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Beam Therapeutics (BEAM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Precision BioSciences (DTIL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), BrightSpring Health Services, Inc. (BTSG) and AgomAb Therapeutics NV ADR (AGMB) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), uniQure (QURE) - The Globe and Mail
B.Riley initiates Agomab Therapeutics stock with buy rating - Investing.com India
B. Riley Initiates AgomAb Therapeutics at Buy With $34 Price Target - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), COMPASS Pathways (CMPS) and Alkermes (ALKS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP) and Mettler-Toledo (MTD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
AGMBAgomAb Therapeutics NV ADR Short Interest - Finviz
AgomAb Therapeutics NV ADR Actuals & Estimates (NASDAQ:AGMB) - TradingView
AGMB Forecast — Price Target — Prediction for 2027 - TradingView
Agomab announces Phase 2b study design for Crohn’s disease drug - Investing.com
Form 6K Agomab Therapeutics Nv For: 23 June By Investing.com - Investing.com India
This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday - Sahm
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
H.C. Wainwright initiates Agomab stock coverage with buy rating - Investing.com
Agomab Announces Results of Annual General Meeting - GlobeNewswire Inc.
Why AgomAb (AGMB) is a smarter play than most realize (Drops Hard) 2026-05-08BPI Bear Correction - The Legal Advocate
Double BottomStock ScreenerCharts - Finviz
Agomab Posts 2025 Loss, Fortifies Cash After IPO and Targets Key 2026 Trial Milestones - The Globe and Mail
AgomAb (NASDAQ: AGMB) posts €62.5m loss and funds operations into 2029 - Stock Titan
AGMB Technical Analysis | Trend, Signals & Chart Patterns | AGOMAB THERAPEUTICS NV (NASDAQ:AGMB) - ChartMill
United Health Group, Viacom among market cap stock movers on Tuesday - Investing.com
Reviewing Prime Medicine (NASDAQ:PRME) and AgomAb Therapeutics (NASDAQ:AGMB) - Defense World
Agomab receives U.S. patent for lung fibrosis drug candidate By Investing.com - Investing.com India
Agomab receives U.S. patent for lung fibrosis drug candidate - Investing.com
Total equity of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total liabilities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total liabilities & shareholders' equities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
Total debt of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Balance Sheet – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Cash Flow – DUS:M5E - TradingView
EBITDA per share of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
AgomAb Therapeutics NV ADR Income Statement – DUS:M5E - TradingView
Net income of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm
Tangible book value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
Cash per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView
AgomAb Therapeutics NV ADR Income Statement – TRADEGATE:M5E - TradingView
What is the current Price Target and Forecast for AgomAb Therapeutics NV (AGMB) - Zacks Investment Research
Agomab closes $200 million IPO on NASDAQ - Investing.com India
EQT Life Sciences-Backed AgomAb Falls After $200 Million IPO - livemint.com
AGMB: AgomAb Therapeutics NVADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
EQT Life Sciences-Backed AgomAb Falls 8% After $200 Million IPO - Bloomberg.com
AgomAb Therapeutics NV (AGMB) stock price, news, quote and history - Yahoo Finance UK
Agomab Announces Pricing of Initial Public Offering - Yahoo Finance
AGMB Stock Price and Chart — NASDAQ:AGMB - TradingView
AGMB Stock Price | Analyst Target 34.00 & Consensus - eToro
Convert Adroverse ADR to United States Dollar USD - Coinbase
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):